Hengrui Pharma Presents 64 Studies at ESMO 2026, Record for Chinese Oncology Company
Hengrui Pharma presents 64 studies at ESMO 2026, a record for the Chinese oncology company showcasing 14 approved innovative...
Editor's Choice
Atrium Therapeutics Doses First Patient in ATR-1072 Trial for PRKAG2 Syndrome
Atrium Therapeutics doses first patient in ATR-1072 trial for PRKAG2 syndrome, targeting the genetic cause of cardiac disease.
Zemprocitinib Maintains ACR20 Response in 90% of RA Patients at 76 Weeks
Zemprocitinib maintains ACR20 response in 90% of RA patients at 76 weeks in Phase III trial, with consistent safety...
Qutenza meets primary pain endpoint in post-surgical neuropathy trial
Qutenza meets primary pain endpoint in post-surgical neuropathy trial, showing sustained benefit over ten months in extension phase.
AI Is Already Inside the Doctor’s Visit. The Question Is Whether It’s Helping or Hunting for Billable Findings.
More than half of physicians now use clinical AI regularly, but new data shows AI systems ordered tests at...
A Patient Died in BMS’s MS CAR-T Trial. No One Can Say Why.
A Phase 1 multiple sclerosis patient died 44 days after a zola-cel infusion. BMS says confounding factors prevent it...
Same Protocol, Different State, Different Answer: How Regional Coverage Breaks Multi-Site MCAs
MAC discretion means the same lab draw can be covered at one site and not another. Here is how...
MDT-BRIDGE Phase 2 Data Signals a Protocol-Driven Model for Adaptive Resectability Assessment in Neoadjuvant NSCLC
The MDT-BRIDGE trial's 142-patient neoadjuvant durvalumab dataset introduces a multidisciplinary reassessment architecture that FDA's existing perioperative…
Medrio launches three-tier Early Adopter Program for clinical trial software
Medrio's Early Adopter Program offers three tiers of discounted access to clinical trial software, with Level 2 participants running...
AI Adoption in Clinical Trials Slowed by Regulatory Gaps, Not Technology Limits
Regulatory gaps and organizational challenges slow AI adoption in clinical trials despite proven 90% reductions in data aggregation time.